Who are Calcipotriene Foam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Calcijex, Calcitriol capsules, Daivonex® scalp solution, calcipotriol hydrate [Daivonex], Vectical Ointment, Dovonex® = calcipotriol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/calcipotriene-foam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Calcipotriene Foam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcipotriene Foam (Calcipotriene Foam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D3 analog. Area: Dermatology.

phase 3 Vitamin D3 analog Vitamin D receptor (VDR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Calcipotriene Foam (Calcipotriene Foam) — Stiefel, a GSK Company. Calcipotriene is a vitamin D3 analog that binds to vitamin D receptors on skin cells to regulate cell proliferation and differentiation, reducing excessive skin cell growth characteristic of psoriasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Calcipotriene Foam TARGET	Calcipotriene Foam	Stiefel, a GSK Company	phase 3	Vitamin D3 analog	Vitamin D receptor (VDR)
Calcijex	CALCITRIOL	Esjay Pharma	marketed	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Calcitriol capsules	Calcitriol capsules	Indonesia University	marketed	Vitamin D3 Analog [EPC]
Daivonex® scalp solution	Daivonex® scalp solution	LEO Pharma	marketed	Vitamin D3 analogue	Vitamin D receptor (VDR)
calcipotriol hydrate [Daivonex]	calcipotriol hydrate [Daivonex]	Hoffmann-La Roche	marketed	Vitamin D3 analog	Vitamin D receptor (VDR)
Vectical Ointment	Vectical Ointment	University of California, San Francisco	marketed	Vitamin D3 analog	Vitamin D receptor (VDR)
Dovonex® = calcipotriol	Dovonex® = calcipotriol	LEO Pharma	phase 3	Vitamin D3 analog	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D3 analog class)

LEO Pharma · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
Stiefel, a GSK Company · 1 drug in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calcipotriene Foam — Competitive Intelligence Brief. https://druglandscape.com/ci/calcipotriene-foam. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing